Aviragen Therapeutics (AVIR) Tops Q4 EPS by 3c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.41), $0.03 better than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• S&P 500 may pull back before midterms, but Citi says buy the dip
• BMO starts chip stocks coverage: Here are its preferred picks